Inventor · disambiguated record
Weiqi Lin
Also filed as: LIN WEIQI
11 granted patents·31 pending applications·201 citations·filing 2001–2025
90Inventor score
Top patents by PatentIndex Score
42 records- 0195US10786517B2Uses of oxygenated cholesterol sulfates (OCS)UNIV VIRGINIA COMMONWEALTH·Filed 2019·Granted Sep 29, 2020·4 cites·14 claims
- 0289US10682340B2Depot formulationsDURECT CORP·Filed 2017·Granted Jun 16, 2020·4 cites·19 claims
- 0388US11612609B2Uses of oxygenated cholesterol sulfates (OCS)UNIV VIRGINIA COMMONWEALTH·Filed 2020·Granted Mar 28, 2023·1 cites·21 claims
- 0487US7798987B2Apparatus and method for piercing skin with microprotrusionsALZA CORP·Filed 2005·Granted Sep 21, 2010·42 cites·10 claims
- 0585US7579013B2Formulations for coated microprojections containing non-volatile counterionsALZA CORP·Filed 2004·Granted Aug 25, 2009·19 cites·15 claims
- 0684US7419481B2Apparatus and method for piercing skin with microprotrusionsALZA CORP·Filed 2005·Granted Sep 2, 2008·37 cites·3 claims
- 0783US2023310458A1Uses of oxygenated cholesterol sulfates (ocs)UNIV VIRGINIA COMMONWEALTH·Filed 2023·Application pending·0 cites
- 0881US10272097B2Uses of oxygenated cholesterol sulfates (OCS)UNIV VIRGINIA COMMONWEALTH·Filed 2014·Granted Apr 30, 2019·3 cites·18 claims
- 0980US10668011B2Depot formulationsDURECT CORP·Filed 2017·Granted Jun 2, 2020·1 cites·10 claims
- 1079US11406646B2Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 1178US12226423B2Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2022·Granted Feb 18, 2025·0 cites·20 claims
- 1278US7131960B2Apparatus and method for piercing skin with microprotrusionsALZA CORP·Filed 2001·Granted Nov 7, 2006·89 cites·10 claims
- 1375US2023372361A1Use of oxygenated cholesterol sulfates for treating inflammatory conditionsDURECT CORP·Filed 2021·Application pending·0 cites
- 1474US2023233580A1Use of oxygenated cholesterol sulfates for cancers and non-cancerous transformations related to epstein-barr virusDURECT CORP·Filed 2021·Application pending·0 cites
- 1574US2023285416A1Use of oxygenated cholesterol sulfates for treating at least one of insulin resistance, diabetes, and prediabetesDURECT CORP·Filed 2021·Application pending·0 cites
- 1674US2023293551A1Use of oxygenated cholesterol sulfates for treating autoimmune conditionsDURECT CORP·Filed 2021·Application pending·0 cites
- 1774US2023218639A1Use of oxygenated cholesterol sulfates for treating neurological conditions, neurodegenerative diseases, and addictionDURECT CORP·Filed 2021·Application pending·0 cites
- 1868US2008226687A1Drug delivery and method having coated microprojections incorporating vasoconstrictorsALZA CORP·Filed 2008·Application pending·0 cites
- 1966US2025249021A1Compositions Comprising 5-Cholesten-3, 25-Diol, 3-Sulfate (25HC3S) or Pharmaceutically Acceptable Salt Thereof And at Least One Cyclic OligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2025·Application pending·0 cites
- 2063US2022175798A1Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglycerideDURECT CORP·Filed 2021·Application pending·0 cites
- 2159US2021169902A1Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesionsUNIV VIRGINIA COMMONWEALTH·Filed 2020·Application pending·0 cites
- 2258US2020383957A1Depot formulationsDURECT CORP·Filed 2020·Application pending·0 cites
- 2358US2020352852A1Depot formulationsDURECT CORP·Filed 2020·Application pending·0 cites
- 2458US2004115167A1Drug delivery device and method having coated microprojections incorporating vasoconstrictorsFiled 2003·Application pending·0 cites
- 2557US2024425545A125-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, SameDURECT CORP·Filed 2022·Application pending·0 cites
- 2656US2005153873A1Frequency assisted transdermal agent delivery method and systemFiled 2004·Application pending·0 cites
- 2756US2023181602A1Treatment of non-alcoholic steatohepatitis (nash)DURECT CORP·Filed 2021·Application pending·0 cites
- 2855US2019374554A1Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesionsUNIV VIRGINIA COMMONWEALTH·Filed 2017·Application pending·0 cites
- 2955US2023181601A1Treatment of non-alcoholic steatohepatitis (nash)DURECT CORP·Filed 2021·Application pending·0 cites
- 3055US2005112135A1Ultrasound assisted transdermal vaccine delivery method and systemFiled 2004·Application pending·0 cites
- 3154US2023141965A1Treatment of infectious diseasesDURECT CORP·Filed 2021·Application pending·0 cites
- 3253US2022378802A1Treatment of alcoholic hepatitisDURECT CORP·Filed 2020·Application pending·0 cites
- 3353US2005089554A1Apparatus and method for enhancing transdermal drug deliveryFiled 2004·Application pending·0 cites
- 3453US2023365619A1Crystalline sodium cholesteryl sulfateDURECT CORP·Filed 2021·Application pending·0 cites
- 3553US2020222430A1Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglycerideDURECT CORP·Filed 2017·Application pending·0 cites
- 3652US2023365618A1Crystalline thiocholesterolDURECT CORP·Filed 2021·Application pending·0 cites
- 3752US2004096455A1Transdermal vaccine delivery device having coated microprotrusionsFiled 2003·Application pending·0 cites
- 3851US2006204562A1Microprojection arrays with improved biocompatibilityCORMIER MICHEL J·Filed 2006·Application pending·0 cites
- 3951US2019269695A1Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2017·Application pending·0 cites
- 4048US2023357308A1Crystalline sodium cholesteryl sulfonateDURECT CORP·Filed 2021·Application pending·0 cites
- 4142US2005123507A1Formulations for coated microprojections having controlled solubilityFiled 2005·Application pending·0 cites
- 4240US2005106226A1Pretreatment method and system for enhancing transdermal drug deliveryFiled 2004·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Weiqi Lin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →